グリコシル化バイオシミラーの世界市場規模・現状・予測2021年-2027年

QYResearchが発行した調査報告書(QY21APR2597)
◆英語タイトル:Global Glycosylated Biosimilars Market Size, Status and Forecast 2021-2027
◆商品コード:QY21APR2597
◆発行会社(リサーチ会社):QYResearch
◆発行日:2021年4月
◆ページ数:98
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥499,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥748,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査資料では、グリコシル化バイオシミラーの世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(mAb、EPO)、用途別市場規模(腫瘍、慢性疾患、自己免疫疾患、血液疾患、成長ホルモン欠乏症、感染症、その他)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・グリコシル化バイオシミラーの市場動向
・企業の競争状況、市場シェア
・グリコシル化バイオシミラーの種類別市場規模(mAb、EPO)
・グリコシル化バイオシミラーの用途別市場規模(腫瘍、慢性疾患、自己免疫疾患、血液疾患、成長ホルモン欠乏症、感染症、その他)
・グリコシル化バイオシミラーの北米市場規模2016-2027(アメリカ、カナダ)
・グリコシル化バイオシミラーの欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・グリコシル化バイオシミラーのアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・グリコシル化バイオシミラーの中南米市場規模2016-2027(メキシコ、ブラジル)
・グリコシル化バイオシミラーの中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Sandoz、Pfizer、Teva Pahrmaceutical、Celltrion、Biocon、Amgen、Samsung Biologics、Mylan、Dr. Reddy's Laboratories、Stada Arzneimittel AG)
・結論
【レポートの概要】

Glycosylated Biosimilars include mA, EPO etc in this report.

Market Analysis and Insights: Global Glycosylated Biosimilars Market
The global Glycosylated Biosimilars market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Glycosylated Biosimilars market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Glycosylated Biosimilars market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Glycosylated Biosimilars market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Glycosylated Biosimilars market.

Global Glycosylated Biosimilars Scope and Market Size
Glycosylated Biosimilars market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Glycosylated Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
mAb
EPO

Segment by Application
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Other Diseases

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Sandoz
Pfizer
Teva Pahrmaceutical
Celltrion
Biocon
Amgen
Samsung Biologics
Mylan
Dr. Reddy’s Laboratories

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Glycosylated Biosimilars Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 mAb
1.2.3 EPO
1.3 Market by Application
1.3.1 Global Glycosylated Biosimilars Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Oncology
1.3.3 Chronic Diseases
1.3.4 Autoimmune Diseases
1.3.5 Blood Disorders
1.3.6 Growth Hormone Deficiency
1.3.7 Infectious Diseases
1.3.8 Other Diseases
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Glycosylated Biosimilars Market Perspective (2016-2027)
2.2 Glycosylated Biosimilars Growth Trends by Regions
2.2.1 Glycosylated Biosimilars Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Glycosylated Biosimilars Historic Market Share by Regions (2016-2021)
2.2.3 Glycosylated Biosimilars Forecasted Market Size by Regions (2022-2027)
2.3 Glycosylated Biosimilars Industry Dynamic
2.3.1 Glycosylated Biosimilars Market Trends
2.3.2 Glycosylated Biosimilars Market Drivers
2.3.3 Glycosylated Biosimilars Market Challenges
2.3.4 Glycosylated Biosimilars Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Glycosylated Biosimilars Players by Revenue
3.1.1 Global Top Glycosylated Biosimilars Players by Revenue (2016-2021)
3.1.2 Global Glycosylated Biosimilars Revenue Market Share by Players (2016-2021)
3.2 Global Glycosylated Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Glycosylated Biosimilars Revenue
3.4 Global Glycosylated Biosimilars Market Concentration Ratio
3.4.1 Global Glycosylated Biosimilars Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Glycosylated Biosimilars Revenue in 2020
3.5 Glycosylated Biosimilars Key Players Head office and Area Served
3.6 Key Players Glycosylated Biosimilars Product Solution and Service
3.7 Date of Enter into Glycosylated Biosimilars Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Glycosylated Biosimilars Breakdown Data by Type
4.1 Global Glycosylated Biosimilars Historic Market Size by Type (2016-2021)
4.2 Global Glycosylated Biosimilars Forecasted Market Size by Type (2022-2027)

5 Glycosylated Biosimilars Breakdown Data by Application
5.1 Global Glycosylated Biosimilars Historic Market Size by Application (2016-2021)
5.2 Global Glycosylated Biosimilars Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Glycosylated Biosimilars Market Size (2016-2027)
6.2 North America Glycosylated Biosimilars Market Size by Type
6.2.1 North America Glycosylated Biosimilars Market Size by Type (2016-2021)
6.2.2 North America Glycosylated Biosimilars Market Size by Type (2022-2027)
6.2.3 North America Glycosylated Biosimilars Market Size by Type (2016-2027)
6.3 North America Glycosylated Biosimilars Market Size by Application
6.3.1 North America Glycosylated Biosimilars Market Size by Application (2016-2021)
6.3.2 North America Glycosylated Biosimilars Market Size by Application (2022-2027)
6.3.3 North America Glycosylated Biosimilars Market Size by Application (2016-2027)
6.4 North America Glycosylated Biosimilars Market Size by Country
6.4.1 North America Glycosylated Biosimilars Market Size by Country (2016-2021)
6.4.2 North America Glycosylated Biosimilars Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Glycosylated Biosimilars Market Size (2016-2027)
7.2 Europe Glycosylated Biosimilars Market Size by Type
7.2.1 Europe Glycosylated Biosimilars Market Size by Type (2016-2021)
7.2.2 Europe Glycosylated Biosimilars Market Size by Type (2022-2027)
7.2.3 Europe Glycosylated Biosimilars Market Size by Type (2016-2027)
7.3 Europe Glycosylated Biosimilars Market Size by Application
7.3.1 Europe Glycosylated Biosimilars Market Size by Application (2016-2021)
7.3.2 Europe Glycosylated Biosimilars Market Size by Application (2022-2027)
7.3.3 Europe Glycosylated Biosimilars Market Size by Application (2016-2027)
7.4 Europe Glycosylated Biosimilars Market Size by Country
7.4.1 Europe Glycosylated Biosimilars Market Size by Country (2016-2021)
7.4.2 Europe Glycosylated Biosimilars Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Glycosylated Biosimilars Market Size (2016-2027)
8.2 Asia-Pacific Glycosylated Biosimilars Market Size by Type
8.2.1 Asia-Pacific Glycosylated Biosimilars Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Glycosylated Biosimilars Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Glycosylated Biosimilars Market Size by Type (2016-2027)
8.3 Asia-Pacific Glycosylated Biosimilars Market Size by Application
8.3.1 Asia-Pacific Glycosylated Biosimilars Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Glycosylated Biosimilars Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Glycosylated Biosimilars Market Size by Application (2016-2027)
8.4 Asia-Pacific Glycosylated Biosimilars Market Size by Region
8.4.1 Asia-Pacific Glycosylated Biosimilars Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Glycosylated Biosimilars Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Glycosylated Biosimilars Market Size (2016-2027)
9.2 Latin America Glycosylated Biosimilars Market Size by Type
9.2.1 Latin America Glycosylated Biosimilars Market Size by Type (2016-2021)
9.2.2 Latin America Glycosylated Biosimilars Market Size by Type (2022-2027)
9.2.3 Latin America Glycosylated Biosimilars Market Size by Type (2016-2027)
9.3 Latin America Glycosylated Biosimilars Market Size by Application
9.3.1 Latin America Glycosylated Biosimilars Market Size by Application (2016-2021)
9.3.2 Latin America Glycosylated Biosimilars Market Size by Application (2022-2027)
9.3.3 Latin America Glycosylated Biosimilars Market Size by Application (2016-2027)
9.4 Latin America Glycosylated Biosimilars Market Size by Country
9.4.1 Latin America Glycosylated Biosimilars Market Size by Country (2016-2021)
9.4.2 Latin America Glycosylated Biosimilars Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Glycosylated Biosimilars Market Size (2016-2027)
10.2 Middle East & Africa Glycosylated Biosimilars Market Size by Type
10.2.1 Middle East & Africa Glycosylated Biosimilars Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Glycosylated Biosimilars Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Glycosylated Biosimilars Market Size by Type (2016-2027)
10.3 Middle East & Africa Glycosylated Biosimilars Market Size by Application
10.3.1 Middle East & Africa Glycosylated Biosimilars Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Glycosylated Biosimilars Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Glycosylated Biosimilars Market Size by Application (2016-2027)
10.4 Middle East & Africa Glycosylated Biosimilars Market Size by Country
10.4.1 Middle East & Africa Glycosylated Biosimilars Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Glycosylated Biosimilars Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Sandoz
11.1.1 Sandoz Company Details
11.1.2 Sandoz Business Overview
11.1.3 Sandoz Glycosylated Biosimilars Introduction
11.1.4 Sandoz Revenue in Glycosylated Biosimilars Business (2016-2021)
11.1.5 Sandoz Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Glycosylated Biosimilars Introduction
11.2.4 Pfizer Revenue in Glycosylated Biosimilars Business (2016-2021)
11.2.5 Pfizer Recent Development
11.3 Teva Pahrmaceutical
11.3.1 Teva Pahrmaceutical Company Details
11.3.2 Teva Pahrmaceutical Business Overview
11.3.3 Teva Pahrmaceutical Glycosylated Biosimilars Introduction
11.3.4 Teva Pahrmaceutical Revenue in Glycosylated Biosimilars Business (2016-2021)
11.3.5 Teva Pahrmaceutical Recent Development
11.4 Celltrion
11.4.1 Celltrion Company Details
11.4.2 Celltrion Business Overview
11.4.3 Celltrion Glycosylated Biosimilars Introduction
11.4.4 Celltrion Revenue in Glycosylated Biosimilars Business (2016-2021)
11.4.5 Celltrion Recent Development
11.5 Biocon
11.5.1 Biocon Company Details
11.5.2 Biocon Business Overview
11.5.3 Biocon Glycosylated Biosimilars Introduction
11.5.4 Biocon Revenue in Glycosylated Biosimilars Business (2016-2021)
11.5.5 Biocon Recent Development
11.6 Amgen
11.6.1 Amgen Company Details
11.6.2 Amgen Business Overview
11.6.3 Amgen Glycosylated Biosimilars Introduction
11.6.4 Amgen Revenue in Glycosylated Biosimilars Business (2016-2021)
11.6.5 Amgen Recent Development
11.7 Samsung Biologics
11.7.1 Samsung Biologics Company Details
11.7.2 Samsung Biologics Business Overview
11.7.3 Samsung Biologics Glycosylated Biosimilars Introduction
11.7.4 Samsung Biologics Revenue in Glycosylated Biosimilars Business (2016-2021)
11.7.5 Samsung Biologics Recent Development
11.8 Mylan
11.8.1 Mylan Company Details
11.8.2 Mylan Business Overview
11.8.3 Mylan Glycosylated Biosimilars Introduction
11.8.4 Mylan Revenue in Glycosylated Biosimilars Business (2016-2021)
11.8.5 Mylan Recent Development
11.9 Dr. Reddy’s Laboratories
11.9.1 Dr. Reddy’s Laboratories Company Details
11.9.2 Dr. Reddy’s Laboratories Business Overview
11.9.3 Dr. Reddy’s Laboratories Glycosylated Biosimilars Introduction
11.9.4 Dr. Reddy’s Laboratories Revenue in Glycosylated Biosimilars Business (2016-2021)
11.9.5 Dr. Reddy’s Laboratories Recent Development
11.10 Stada Arzneimittel AG
11.10.1 Stada Arzneimittel AG Company Details
11.10.2 Stada Arzneimittel AG Business Overview
11.10.3 Stada Arzneimittel AG Glycosylated Biosimilars Introduction
11.10.4 Stada Arzneimittel AG Revenue in Glycosylated Biosimilars Business (2016-2021)
11.10.5 Stada Arzneimittel AG Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ グリコシル化バイオシミラーの世界市場規模・現状・予測2021年-2027年(Global Glycosylated Biosimilars Market Size, Status and Forecast 2021-2027)]についてメールでお問い合わせはこちらでお願いします。